XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Capital and Financing Transactions (Tables)
6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
Schedule of revolving credit facilities and term loans
At June 30, 2016 and December 31, 2015, the carrying amounts of the Company's notes payable to banks, net were $543.7 million and $542.9 million, respectively, including $550.0 million outstanding under the following term loans (in thousands):
Credit Facilities
 
Interest Rate
 
Initial Maturity
 
Outstanding Balance at June 30, 2016
 
Outstanding Balance at December 31, 2015
$10.0 Million Working Capital Revolving Credit Facility
 
1.8%
 
03/30/2018
 
$

 
$

$450.0 Million Revolving Credit Facility
 
1.8%
 
03/30/2018
 

 

$250.0 Million Five-Year Term Loan
 
2.6%
 
03/29/2019
 
250,000

 
250,000

$200.0 Million Five-Year Term Loan
 
1.8%
 
06/26/2020
 
200,000

 
200,000

$100.0 Million Seven-Year Term Loan
 
4.4%
 
03/31/2021
 
100,000

 
100,000

Notes payable to banks outstanding
 
 
 
 
 
550,000

 
550,000

Unamortized debt issuance costs, net
 
 
 
 
 
(6,258
)
 
(7,120
)
Notes payable to banks, net
 
 
 
 
 
$
543,742

 
$
542,880

Schedule of the effect of derivative financial instruments on consolidated statements of operations and comprehensive income (loss)
The table below presents the effect of the Company's derivative financial instruments on the Company's consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2016 and 2015 (in thousands):
Derivatives in Cash Flow Hedging Relationships (Interest Rate Swaps)
Three Months Ended June 30,
 
Six Months Ended June 30,
2016
 
2015
 
2016
 
2015
Amount of gain (loss) recognized in other comprehensive income (loss) on derivatives
$
(2,341
)
 
$
680

 
$
(8,017
)
 
$
(4,425
)
Net loss reclassified from accumulated other comprehensive income (loss) into earnings
$
1,353

 
$
1,734

 
$
2,716

 
$
3,592

Amount of loss recognized in income on derivatives (ineffective portion, reclassifications of missed forecasted transactions and amounts excluded from effectiveness testing)
$
11

 
$
1,221

 
$
37

 
$
1,245